UNSPSC 51161720: Roflumilast

This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H14Cl2F2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0P6C6ZOP5U, chemically known as 3-cyclopropylmethoxy-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide but generally known as roflumilast, which bears US NIH Compound Identifier 449193. European Medicines Agency schedules Roflumilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10358MIG.

UNSPSC 51161720 Roflumilast is a Commodity code nominally designating a specific bronchodilator pharmaceutical, yet recent state and local procurement activity under this code does not reflect purchases of roflumilast itself. Instead, the code has been applied to two materially different health-services procurements: emergency medical supplies (naloxone and drug deactivation systems) and on-site employer pharmacy services. The mismatch between the code's nominal scope and actual buying activity suggests that state and local issuing bodies are using this code as a catch-all for pharmaceutical-adjacent services rather than for the drug compound the code name specifies. Issuing bodies applying the code include a county health authority (Seminole County, Florida) and a county government employee benefits office (Hall County, Georgia), indicating that the code reaches both public health and employer-group-health procurement functions within local government.

Recent activity appears concentrated in the Southeast, with solicitations posted from Florida and Georgia in mid-2026. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, a two-year initial term with one-year renewal option, and a July 26, 2023 response deadline. Hall County, Georgia issued RFQ/P #47-010 in May 2026 to procure comprehensive on-site pharmacy services for approximately 3,005 eligible individuals enrolled in the county's group health insurance plans, with an 80/20 technical-to-cost scoring structure, a June 4, 2026 response deadline, and a one-year initial contract term with four optional one-year renewals beginning January 1, 2027. The code shows limited recent activity overall, and the two opportunities reflect distinct procurement functions with no clear connection to roflumilast itself.